Expert Recommendations in Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

MYSummit Myeloma Conference - Cancelled

Due to the impact of COVID-19, the MYSummit Conference
has been cancelled

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

Featured Content

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Myeloma News

Does Elotuzumab Improve PFS in High-Risk Myeloma?

Source: Multiple Myeloma – ASH Clinical News The addition of the anti-SLAMF7 antibody elotuzumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and maintenance did not improve outcomes for patients with previously untreated high-risk multiple myeloma...

Recent Publications

Twitter Discussions

MM_Hub: CONGRESS|#EHA2021|@szusmani @LevineCancer presented poster for results from CARTITUDE-1 study where a single infusion of cita-cel yielded deep & durable responses in heavily pretreated MM pts with manageable safety profile at RP2D #mmsm #myeloma

CONGRESS|#EHA2021|@szusmani @LevineCancerpresented poster for results from CARTITUDE-1 study where a single infusion of cita-cel yielded deep & durable responses in heavily pretreated MM pts with manageable safety profile at RP2D #mmsm #myeloma...

MM_Hub: CONGRESS|#EHA2021| Juan-José Garcés @idisnanavarra presented that circulating tumor cells (CTC) were the most relevant prognostic factor at baseline in MM pts. Undetectable MRD should be the treatment endpoint for CTC elevated pts as they showed long-term survival #mmsm #myeloma

CONGRESS|#EHA2021| Juan-José Garcés @idisnanavarra presented that circulating tumor cells (CTC) were the most relevant prognostic factor at baseline in MM pts. Undetectable MRD should be the treatment endpoint for CTC elevated pts as they showed long-term survival...

MM_Hub: CONGRESS|#EHA2021| Jason Valent, Taussig Cancer Institute presented study on safety & tolerability through 4 weeks of treatment with CAEL-101+CyBorD & CAEL-101+CyBorD+daratumumab in amyloidosis pts. 1000mg/sq.m was well-tolerated. #mmsm,#myeloma

CONGRESS|#EHA2021| Jason Valent, Taussig Cancer Institute presented study on safety & tolerability through 4 weeks of treatment with CAEL-101+CyBorD & CAEL-101+CyBorD+daratumumab in amyloidosis pts. 1000mg/sq.m was well-tolerated. #mmsm,#myeloma...